Literature DB >> 21093731

Utility of Charcot-Marie-Tooth Neuropathy Score in children with type 1A disease.

Jana Haberlová1, Pavel Seeman.   

Abstract

The aim of this study was to evaluate the utility of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) for evaluation of disease severity in young children with Charcot-Marie-Tooth type 1A. Current validated scoring scales for Charcot-Marie-Tooth are the CMTNS and the Neuropathy Impairment Score (NIS). Both work well for adult patients, and usually also for children over 10 years of age. There is no validation of scales for young children. Children with genetically proven Charcot-Marie-Tooth type 1A disease (n = 20, aged 3 to 10 years) were examined clinically, followed by electrophysiologic examination, and were scored under the CMTNS scale. The clinical symptoms were mild; the two most frequent symptoms were difficulty in heel walking and lower limb areflexia. The score was maximally abnormal in four of the nine categories. Categories for sensation, sensory symptoms, and motor symptoms of the arms were normal in all cases. The score was below 8 for all tested children. To conclude, the CMTNS in children aged 10 years and younger has limited sensitivity; out of nine categories, only four are useful. Thus, evaluation of disease severity and progression in young children with Charcot-Marie-Tooth disease remains limited, and there is need for other, effective scoring systems.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21093731     DOI: 10.1016/j.pediatrneurol.2010.06.004

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  6 in total

1.  Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.

Authors:  Joshua Burns; Robert Ouvrier; Tim Estilow; Rosemary Shy; Matilde Laurá; Julie F Pallant; Monkol Lek; Francesco Muntoni; Mary M Reilly; Davide Pareyson; Gyula Acsadi; Michael E Shy; Richard S Finkel
Journal:  Ann Neurol       Date:  2012-05       Impact factor: 10.422

2.  Transitioning outcome measures: relationship between the CMTPedS and CMTNSv2 in children, adolescents, and young adults with Charcot-Marie-Tooth disease.

Authors:  Joshua Burns; Manoj Menezes; Richard S Finkel; Tim Estilow; Isabella Moroni; Emanuela Pagliano; Matilde Laurá; Francesco Muntoni; David N Herrmann; Kate Eichinger; Rosemary Shy; Davide Pareyson; Mary M Reilly; Michael E Shy
Journal:  J Peripher Nerv Syst       Date:  2013-06       Impact factor: 3.494

3.  Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.

Authors:  Emanuela Pagliano; Isabella Moroni; Giovanni Baranello; Anita Magro; Alessia Marchi; Sara Bulgheroni; Maurizio Ferrarin; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

4.  Hidden hearing loss in patients with Charcot-Marie-Tooth disease type 1A.

Authors:  Ji Eun Choi; Jin Myoung Seok; Jungmin Ahn; Yoon Sang Ji; Kyung Myun Lee; Sung Hwa Hong; Byung-Ok Choi; Il Joon Moon
Journal:  Sci Rep       Date:  2018-07-09       Impact factor: 4.379

5.  Muscle fat quantification using magnetic resonance imaging: case-control study of Charcot-Marie-Tooth disease patients and volunteers.

Authors:  Hyun Su Kim; Young Cheol Yoon; Byung-Ok Choi; Wook Jin; Jang Gyu Cha
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-03-15       Impact factor: 12.910

6.  Genetic Spectrum of Inherited Neuropathies in India.

Authors:  Shivani Sharma; Periyasamy Govindaraj; Yasha T Chickabasaviah; Ramesh Siram; Akhilesh Shroti; Doniparthi V Seshagiri; Monojit Debnath; Parayil S Bindu; Arun B Taly; Madhu Nagappa
Journal:  Ann Indian Acad Neurol       Date:  2022-06-14       Impact factor: 1.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.